文献速递介入腹部PETCT

治疗后PET/CT剂量学预测肝细胞癌经动脉放射栓塞后对侧肝叶肥大

Post-Treatment PET/CT Dosimetry to Predict Contralateral Lobe Hypertrophy After Transarterial Radioembolization for Hepatocellular Carcinoma.
PubMed 文献 · Korean J Radiol · 2025-09-24

本回顾性单中心研究纳入40例未接受过治疗的右叶肝细胞癌患者,分析TARE后16-24小时⁹⁰Y PET/CT体素剂量学对左叶肥大的预测价值。结果显示非肿瘤右叶平均吸收剂量是左叶肥大的唯一独立剂量学预测因子(R²=0.556,P<0.001),血小板计数也独立预测(R²=0.221,P=0.003)。作者认为该剂量学方法尤其结合血小板计数可有效预测对侧肥大,但需更大前瞻性队列验证。

要点

  • 非肿瘤右叶平均吸收剂量与左叶肥大相关最强(ρ=0.662,P<0.001)。
  • 多变量回归中非肿瘤右叶平均剂量是唯一独立剂量学预测因子(R²=0.556)。
  • 血小板≥130×10³/µL者剂量与肥大相关性更强(ρ=0.847 vs 0.429)。

核心结论

  • TARE后⁹⁰Y PET/CT剂量学,尤其结合血小板计数,是预测未治疗肝细胞癌患者对侧肝叶肥大的有效方法;需更大前瞻性队列验证。

研究设计与样本

  • 回顾性单中心研究,纳入40例未治疗右叶肝细胞癌患者(年龄66.4±12.5岁,男29例、女11例),接受⁹⁰Y玻璃微球TARE。

关键影像表现/征象

  • 治疗后16-24小时行⁹⁰Y PET/CT生成体素吸收剂量图,获取全肝、右叶及非肿瘤右叶剂量直方图。
  • 计算各区域平均吸收剂量及接受≥50 Gy(P₅₀)和≥100 Gy(P₁₀₀)的体积比例。
  • 治疗后2-4个月随访CT,用CT体积测量法测量左叶体积增加百分比。

诊断标准与关键数值

  • 左叶体积中位增加12.7%(四分位距5.7%-28.1%)。
  • 非肿瘤右叶平均剂量与左叶肥大ρ=0.662(P<0.001),P₅₀与左叶肥大ρ=0.672(P<0.001)。
  • 多变量回归中非肿瘤右叶平均剂量R²=0.556(P<0.001),血小板计数R²=0.221(P=0.003)。
  • 血小板≥130×10³/µL者非肿瘤右叶剂量与左叶肥大ρ=0.847(P<0.001),血小板降低者ρ=0.429(P=0.129)。

临床应用与阅片要点

  • 作者认为TARE后⁹⁰Y PET/CT剂量学尤其结合血小板计数可用于预测对侧肝叶肥大。
  • 作者指出需更大前瞻性队列研究验证这些预测策略。

局限性

  • 原文报告需更大前瞻性队列研究验证这些预测策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Image-based dosimetry in transarterial radioembolization (TARE) has been proposed for the prediction of contralateral lobe hypertrophy as well as tumor response. This study aimed to evaluate the predictive value of post-treatment ⁹⁰Y PET/CT voxel-based dosimetry for post-TARE liver hypertrophy in treatment-naïve patients with hepatocellular carcinoma (HCC).

MATERIALS AND METHODS: This retrospective single-center study included 40 treatment-naïve patients with right lobar HCC (age, 66.4 ± 12.5 years; male:female, 29:11) who underwent TARE with ⁹⁰Y-labeled glass microspheres. Voxel-based absorbed dose maps were generated from ⁹⁰Y PET/CT performed 16-24 hours post-treatment; dose histograms were obtained for the whole liver, right lobe (RL), and non-tumor RL (NRL). Mean absorbed dose and volume proportion receiving ≥50 Gy (P₅₀) and ≥100 Gy (P₁₀₀) for each region were calculated. All patients underwent follow-up CT-2-4 months after treatment, and the percentage increase in left lobe (LL) volume was measured using CT volumetry. The efficacy of dosimetric parameters and conventional clinical factors in predicting LL hypertrophy was analyzed using Spearman's correlation and multivariable regression.

RESULTS: The median LL volume increase was 12.7% (interquartile range, 5.7%-28.1%). The mean absorbed dose (ρ = 0.662, P < 0.001) and P₅₀ (ρ = 0.672, P < 0.001) of NRL showed the strongest correlations with LL hypertrophy. In multivariable regression integrating clinical factors, the mean NRL dose was the only independent dosimetric predictor (R² = 0.556, P < 0.001); platelet count also remained independently predictive (R² = 0.221, P = 0.003). The relationship between NRL dose and LL hypertrophy was markedly stronger in patients with preserved platelet counts (platelet ≥130 × 10³/µL; ρ = 0.847; P < 0.001) than in those with decreased platelet counts (ρ = 0.429; P = 0.129).

CONCLUSION: Post-TARE ⁹⁰Y PET/CT dosimetry, particularly in combination with platelet count, is an effective approach to predict contralateral hypertrophy in treatment-naïve patients with HCC. Further studies with larger prospective cohorts are required to validate these predictive strategies.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Kang YK, Suh M, Choi JW, et al. Post-Treatment PET/CT Dosimetry to Predict Contralateral Lobe Hypertrophy After Transarterial Radioembolization for Hepatocellular Carcinoma. Korean J Radiol. 2025. PMID: 41078019. doi:10.3348/kjr.2025.0867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。